Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL
- 1 August 2018
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 27 (9), 1470-1478
- https://doi.org/10.1177/0961203318777116
Abstract
Objective Rituximab-mediated late-onset neutropenia (LON) has been described in various diseases. We investigated its occurrence, consequences and contributing factors in patients with systemic lupus erythematosus (SLE). Methods Rituximab-treated patients from the Karolinska University Hospital (n=107) were surveyed. LON was defined as an absolute neutrophil count <1500 cells/l, occurring four weeks to two years following rituximab treatment, or later during sustained B-cell depletion. Serum levels of B-cell-related cytokines and growth factors of the myeloid lineage were determined using enzyme-linked immunosorbent assay. Results Thirty-two patients (29.9%) developed LON after a median time of 201.5 days. Thirteen patients were admitted to the hospital; 10 due to fever. Three patients developed critical conditions. BAFF levels increased from baseline (median: 0.62ng/ml) to the post-treatment evaluation (median: 1.16ng/ml; p<0.001); post-treatment levels were higher in the LON group (p=0.021). APRIL levels were higher in the LON group both at baseline (median: 1.54 versus 1.15ng/ml; p=0.027) and post-treatment (median: 2.39 versus 1.11ng/ml; p=0.011). IL-6 and GM-CSF levels decreased in the non-LON group (p8). No association with neutropenia prior to rituximab treatment was documented. Conclusion Post-rituximab LON was a common complication. Although the phenomenon was predominantly self-limiting, several patients developed severe conditions. Distinct roles of BAFF and APRIL are implicated: BAFF may contribute to LON development, whereas high APRIL levels may be predictive. Rituximab-treated SLE patients should be monitored for neutrophil counts, fever and infections.Keywords
Funding Information
- Stiftelsen Professor Nanna Svartz Fond
- Reumatikerförbundet
- Vetenskapsrådet
- Stockholms Läns Landsting
- Karolinska Institutet
- Stiftelsen Konung Gustaf V:s 80-Ã¥rsfond
- Hjärt-Lungfonden
This publication has 44 references indexed in Scilit:
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals Of The Rheumatic Diseases, 2012
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- Neutropenia after rituximab treatmentCurrent Opinion in Hematology, 2012
- B Cell and BAFF Dependence of IFN-α–Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 MiceThe Journal of Immunology, 2011
- Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus ErythematosusScience Translational Medicine, 2011
- Current and novel therapeutics in the treatment of systemic lupus erythematosusJournal of Allergy and Clinical Immunology, 2011
- Neutropenia associated with rituximab therapyCurrent Opinion in Hematology, 2011
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosaJCI Insight, 2008
- Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosusArthritis & Rheumatism, 2003